Characterization of the interleukin-1β-converting enzyme/Ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease. Lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease

American Journal of Pathology

Volumn 154, Issue 5, 1999, Pages 1439-1447

  Izban, Keith F ^a   Wrone Smith, Tamara ^a   Hsi, Eric D ^b   Schnitzer, Bertram ^c   Quevedo, Maria Eugenia ^a   Alkan, Serhan ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FAS ANTIGEN; INTERLEUKIN 1BETA CONVERTING ENZYME; CASP3 PROTEIN, HUMAN; CASPASE; ENZYME PRECURSOR;

APOPTOSIS; ARTICLE; ENZYME ACTIVITY; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; CELL CULTURE; ENZYMOLOGY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPH NODE; LYMPHOCYTE COUNT; PATHOLOGY;

ANTIGENS, CD95; CASPASE 1; CASPASE 3; CASPASES; ENZYME PRECURSORS; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOCYTE COUNT; TUMOR CELLS, CULTURED;

EID: 0032588953     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65398-9     Document Type: Article

References (61)

1. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986, 83:5214-5218
2. Vaul DL, Cory S, Adams JM: Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335:440-442
3. Hengartner MO, Horvitz HR: C. elegans survival gene ced-9 encodes a functional homologue of the mammalian proto-oncogene bcl-2. Cell 1994, 76:665-676
4. Shaham S, Horvitz HR: Developing Caenorhabditis elegans neurons may contain both cell-death protective and killer activities. Genes Dev 1996, 10:578-591
5. Yuan J, Shaham S, Ledoux S, Ellis JM, Horvitz JR: C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 1993, 75:641-652
6. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G: Bcl-XL interacts with Apaf-1, and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998, 95:4386-4391
7. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J: Human ICE/CED-3 protease nomenclature. Cell 1996, 87:171
8. Humke EW, Ni J, Dixit VM: ERIGE, a novel FLICE-activatable caspase. J Biol Chem 1998, 273:15702-15707
9. Schlegel J, Peters I, Orrenius S, Miller DK, Thornberry NA, Yamin TT, Nicholson DW: CPP32/apopain is a key interleukin 1β converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem 1996, 1841-1844
10. Enari M, Hug H, Nagata S: Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995, 375:78-81
11. Enari M, Talanian RV, Wong WW, Nagata S: Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996, 380:723-726
12. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243
13. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992, 267:10709-10715
14. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular, and viral proteins: activation, costimulation and death. Cell 1994, 76:959-962
15. Bump NJ, Hackett M, Hugunin M, Seshagiri S, Brady K, Chen P, Ferenz C, Franklin S, Ghayur T, Li P: Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 1995, 269:1885-1888
16. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995, 16:39-43
17. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice caused by a point mutation in Fas ligand. Cell 1994, 76:969-976
18. Gronbaek K, thor Strafen P, Ahrenkeil V, Klarskov Anderson M, Ebbe Hansen N, Zeuthen J, Hou-Jensen K, Guldenberg P: Somatic fas mutations in non-Hodgkin's lymphomas: association with extranodal disease and autoimmunity. Blood 1998, 92:3018-3024
19. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305
20. Yonehara S, Ishii A, Yonehara M: A cell killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989, 169:1747-1756
21. Suda T, Nagata S: Purification and characterization of the Fas ligand that induces apoptosis. J Exp Med 1994, 179:873-878
22. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the TNF family. Cell 1993, 75:1169-1178
23. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S: Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994, 6:1567-1574
24. von Wasielewski R, Werner M, Fischer R, Hansmann ML, Hubner K, Hasenclever D, Franklin J, Sextro M, Diehl V, Georgii A: Lymphocyte-predominant Hodgkin's disease: An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin's Study Group. Am J Pathol 1997, 150:793-803
25. Harris NL, Jaffe ES, Stein H, Banks P, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392
26. Alkan S, Hsi ED, Wrone-Smith T: CD95 (Fas antigen: APO-1) mediated apoptosis on Hodgkin's disease cell lines. Mod Pathol 1998, 11:162A (abstr. 950)
27. Armstrong RC, Aja T, Xiang J, Gaur S, Krebs JF, Hoang K, Bai X, Korsmeyer SJ, Karanewski DS, Fritz LC, Tomaselli KJ: Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 1996, 271: 16850-16855
28. Los M, Van de Craen M, Penning LC, Schenk H, Westendrop M, Baeuerle PA, Droge W, Krammer PH, Fiers W, Schulze-Osthoff K: Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 1995, 375:81-83
29. L function upstream of the CED-3-like apoptotic proteases. J Biol Chem 1996, 271:4573-4576
30. Darmon AJ, Bleackley RC: An interleukin-1β converting enzyme-like protease is a key component of Fas-mediated apoptosis. J Biol Chem 1996, 271:21699-21702
31. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376:37-43
32. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM: Yama/CPP32b, a mammalian homologue of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995, 81:801-809
33. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW, Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-β-D-Arabinofuranosylcytosine and other DNA-damaging agents. Blood 1996, 6:1936-1943
34. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin K-M: Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997, 8:3118-3129
35. Li F, Srinivasan A, Wang Y, Armstrong RC, Tomaselli KJ, Fritz LC: Cell-specific induction of apoptosis by microinjection of cytochrome c. J Biol Chem 1997, 48:30299-30305
36. Hasenclaver D, and Diehl V: A prognostic score for advanced Hodgkin's disease. New Engl J Med 1998, 339:1506-1514
37. Chhanabhai M, Krajewski S, Krajewska M, Wang HG, Reed JC, Gascoyne RD: Immunohistochemical analysis of interleukin-1β-converting enzyme/Ced-3 family protease CPP32/Yama/Caspase 3 in Hodgkin's disease. Blood 1997, 90:2451-2455
38. Xerri L, Devilard E, Ayello C, Brousset P, Reed JC, Emile J-F, Hassoun J, Parmentier S, Birg F: Cysteine protease CPP32, but not Ich1-L, is expressed in germinal center B cells and their neoplastic counterparts. Hum Pathol 28:912-921
39. Livingston DJ: In vitro and in vivo studies of ICE inhibitors. J Cell Biochem 1997, 64:19-26
40. Shimizu S, Eguchi Y, Kamiike W, Matsuda H, Tsujimoto Y: Bcl-2 expression prevents activation of the ICE protease cascade. Oncogene 1996, 12:2251-2257
41. Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW: Substrate specificities of caspase family proteases. J Biol Chem 1997, 272:9677-9682
42. Zhivotovsky B, Burgess DH, Schlegel J, Porn MI, Vanags D, Orrenius S: Proteases in Fas-mediated apoptosis. J Cell Biochem 1997, 64: 43-49
43. Monney L, Otter I, Olivier R, Ozer HL, Mass AL, Omura S, Borner C: Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by Bcl-2. J Biol Chem 1998, 273:6121-6131
44. Gupta RK, Lister TA, Bodmer JG: The t(14;18) chromosomal translocation and Bcl-2 protein expression in Hodgkin's disease. Leukemia 1994, 8:1337-1341
45. Bhagat SK, Medeiros LJ, Weiss LM, Wang J, Raffeld M, Stetler-Stevenson M: Bcl-2 expression in Hodgkin's disease. Correlation with the t(14;18) translocation and Epstein-Barr virus. Am J Clin Pathol 1993, 99:604-608
46. Alkan S, Ross CW, Hanson CA, Schnitzer B: Epstein-Barr virus bcl-2 protein overexpression are not detected in the neoplastic cells of nodular lymphocyte predominance Hodgkin's disease. Mod Pathol 1995, 8:544-547
47. Rigal-Huguet F, Gopas J, Prinsloo I, Pris J, Delsol G, Reed JC, Schlaifer D, Brousset P, Benharroch D, Krajewski S, Laurent G, Meggetto F: Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease. Blood 1996, 87:2470-2475
48. Schlaifer D, March M, Krajewski S, Laurent G, Pris J, Delsol G, Reed JC, Brousset P: High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. Blood 1995, 85:2671-2674
49. Schlaifer D, Krajewski S, Rigal-Huguet F, Laurent G, Pris J, Delsol G, Reed JC, Brousset P: Bcl-x gene expression in Hodgkin's disease. Leuk Lymphoma 1996, 23:143-146
50. Kubonishi I, Daibata M, Sakuma I, Yoshino T, Sonobe H, Ohtsuki Y, Miyoshi I: Expression of Fas and apoptosis of a Hodgkin's disease cell line (HD-70). Int J Hematol 1997, 65:305-307
51. Xerri L, Devilard E, Hassoun J, Haddad P, Birg F: Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 1997, 11:1868-1877
52. Nguyen PL, Harris NL, Ritz J, Robertson MJ: Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 1996, 148:847-853
53. Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler HG: Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines. Br J Haematol 1997, 96:584-593
54. Krajewski S, Gascoyne RD, Zapata JM, Krajewska M, Kitada S, Chhanabhai M, Horsmann D, Berean K, Piro LD, Fugier-Vivier I, Liu YJ, Wang HG, Reed JC: Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase 3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. Blood 1997, 89: 3817-3825
55. Pinkus GS, Said JW: Hodgkin's disease, lymphocyte predominance type, nodular-further evidence for a B-cell derivation. Am J Pathol 1988, 133:211-217
56. Grossman DM, Hanson CA, Schnitzer B: Simultaneous lymphocyte predominant Hodgkin's disease and large-cell lymphoma. Am J Surg Pathol 1991, 15:668-676
57. Sextro M, Diehl V, Franklin J, Hansmann ML, Anagnostopoulous I, Marafioti T, Stein H: Lymphocyte predominant Hodgkin's disease: a workshop report. Ann Oncol 1996, 7:61-65
58. Algara P, Martinez P, Sanchez L, Villuendas R, Orradre JL, Oliva H, Piris MA: Lymphocyte predominance Hodgkin's disease (nodular paragranuloma): a bcl-2 negative germinal centre lymphoma. Histopathology 1991, 19:69-75
59. L inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 1996, 56:4743-4748
60. Memon SA, Moreno MB, Petrak D, Zacharchuk CM: Bcl-2 blocks glucocorticoid-but not Fas-or activation-induced apoptosis in a T cell hybridoma. J Immunol 1995, 155:4644-4652
61. Moreno MB, Memon SA, Zacharchuk CM: Apoptosis signaling pathways in normal T cells: differential activity of Bcl-2 and IL-1β-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity. J Immunol 1996, 157:3845-3849